These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 21095149

  • 1. Consistency of bone turnover marker and calcium responses to parathyroid hormone (1-84) therapy in postmenopausal osteoporosis.
    Schafer AL, Palermo L, Bauer DC, Bilezikian JP, Sellmeyer DE, Black DM.
    J Clin Densitom; 2011; 14(1):68-73. PubMed ID: 21095149
    [Abstract] [Full Text] [Related]

  • 2. Alendronate does not block the anabolic effect of PTH in postmenopausal osteoporotic women.
    Cosman F, Nieves J, Woelfert L, Shen V, Lindsay R.
    J Bone Miner Res; 1998 Jun; 13(6):1051-5. PubMed ID: 9626638
    [Abstract] [Full Text] [Related]

  • 3. Correlations between biochemical markers of bone turnover and bone density responses in patients with glucocorticoid-induced osteoporosis treated with teriparatide or alendronate.
    Burshell AL, Möricke R, Correa-Rotter R, Chen P, Warner MR, Dalsky GP, Taylor KA, Krege JH.
    Bone; 2010 Apr; 46(4):935-9. PubMed ID: 20060081
    [Abstract] [Full Text] [Related]

  • 4. Monitoring alendronate therapy for osteoporosis.
    Braga de Castro Machado A, Hannon R, Eastell R.
    J Bone Miner Res; 1999 Apr; 14(4):602-8. PubMed ID: 10234582
    [Abstract] [Full Text] [Related]

  • 5. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 6. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.
    J Bone Miner Res; 1998 Sep; 13(9):1431-8. PubMed ID: 9738515
    [Abstract] [Full Text] [Related]

  • 7. Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis.
    Chen P, Satterwhite JH, Licata AA, Lewiecki EM, Sipos AA, Misurski DM, Wagman RB.
    J Bone Miner Res; 2005 Jun; 20(6):962-70. PubMed ID: 15883636
    [Abstract] [Full Text] [Related]

  • 8. Changes in bone markers after once-weekly low-dose alendronate in postmenopausal women with moderate bone loss.
    Choi HJ, Im JA, Kim SH.
    Maturitas; 2008 Jun 20; 60(2):170-6. PubMed ID: 18572334
    [Abstract] [Full Text] [Related]

  • 9. Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial.
    Deal C, Omizo M, Schwartz EN, Eriksen EF, Cantor P, Wang J, Glass EV, Myers SL, Krege JH.
    J Bone Miner Res; 2005 Nov 20; 20(11):1905-11. PubMed ID: 16234962
    [Abstract] [Full Text] [Related]

  • 10. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis.
    Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD.
    J Bone Miner Res; 1996 Mar 20; 11(3):337-49. PubMed ID: 8852944
    [Abstract] [Full Text] [Related]

  • 11. Marked reduction of bone turnover by alendronate attenuates the acute response of bone resorption marker to endogenous parathyroid hormone.
    Zikan V, Stepan JJ.
    Bone; 2009 Apr 20; 44(4):634-8. PubMed ID: 19150421
    [Abstract] [Full Text] [Related]

  • 12. Role of type I collagen C telopeptide, bone-specific alkaline phosphatase and osteocalcin in the assessment of bone status in postmenopausal women.
    Trento LK, Pietropolli A, Ticconi C, Gravotta E, De Martino MU, Fabbri A, Piccione E.
    J Obstet Gynaecol Res; 2009 Feb 20; 35(1):152-9. PubMed ID: 19215563
    [Abstract] [Full Text] [Related]

  • 13. Gender variation in PTH sensitivity and rhythmicity following growth hormone replacement in adult growth hormone-deficient patients.
    White HD, Ahmad AM, Syed AA, Clewes A, Peter R, Vora JP, Fraser WD.
    Clin Endocrinol (Oxf); 2004 Apr 20; 60(4):516-26. PubMed ID: 15049968
    [Abstract] [Full Text] [Related]

  • 14. Effects of simvastatin on bone turnover and BMD: a 1-year randomized controlled trial in postmenopausal osteopenic women.
    Rejnmark L, Buus NH, Vestergaard P, Heickendorff L, Andreasen F, Larsen ML, Mosekilde L.
    J Bone Miner Res; 2004 May 20; 19(5):737-44. PubMed ID: 15068496
    [Abstract] [Full Text] [Related]

  • 15. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, Fracture Intervention Trial Long-Term Extension Research Group.
    J Bone Miner Res; 2004 Aug 20; 19(8):1259-69. PubMed ID: 15231012
    [Abstract] [Full Text] [Related]

  • 16. Effects of growth hormone administration on bone mineral metabolism, PTH sensitivity and PTH secretory rhythm in postmenopausal women with established osteoporosis.
    Joseph F, Ahmad AM, Ul-Haq M, Durham BH, Whittingham P, Fraser WD, Vora JP.
    J Bone Miner Res; 2008 May 20; 23(5):721-9. PubMed ID: 18052753
    [Abstract] [Full Text] [Related]

  • 17. Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk.
    Reginster JY, Sarkar S, Zegels B, Henrotin Y, Bruyere O, Agnusdei D, Collette J.
    Bone; 2004 Feb 20; 34(2):344-51. PubMed ID: 14962813
    [Abstract] [Full Text] [Related]

  • 18. Short-term changes in bone turnover markers and bone mineral density response to parathyroid hormone in postmenopausal women with osteoporosis.
    Bauer DC, Garnero P, Bilezikian JP, Greenspan SL, Ensrud KE, Rosen CJ, Palermo L, Black DM.
    J Clin Endocrinol Metab; 2006 Apr 20; 91(4):1370-5. PubMed ID: 16449339
    [Abstract] [Full Text] [Related]

  • 19. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH.
    Ueda M, Inaba M, Okuno S, Maeno Y, Ishimura E, Yamakawa T, Nishizawa Y.
    Life Sci; 2005 Jul 22; 77(10):1130-9. PubMed ID: 15978265
    [Abstract] [Full Text] [Related]

  • 20. Alendronate stimulation of nocturnal parathyroid hormone secretion: a mechanism to explain the continued improvement in bone mineral density accompanying alendronate therapy.
    Greenspan SL, Holland S, Maitland-Ramsey L, Poku M, Freeman A, Yuan W, Kher U, Gertz B.
    Proc Assoc Am Physicians; 1996 May 22; 108(3):230-8. PubMed ID: 8774056
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.